Larimar Therapeutics (LRMR) Price to FCF (2020 - 2025)
Larimar Therapeutics' (LRMR) quarterly Price to FCF came in at 12019.87 in Q3 2025, down 70673.21% on a YoY basis from N/an in Q3 2024, and down 125918.52% quarter-over-quarter from 9.54 in Q2 2025.
Powered by 
Analysis
Larimar Therapeutics (LRMR) Price to FCF (2020 - 2025) Analysis & Trends
Larimar Therapeutics (LRMR) has reported Price to FCF for 6 consecutive years, with 12019.87 the latest figure, recorded in Q3 2025.
- For the quarter ending Q3 2025, Price to FCF fell 70673.21% year-over-year to 12019.87; the trailing twelve-month figure through Dec 2025 stood at 6.88 (down 98.68% YoY), and the FY2025 full-year result was 2.79, up 19.31% from the prior year.
- Price to FCF retreated to 12019.87 in Q3 2025 per LRMR's latest filing, from 9.54 in the prior quarter.
- Across five years, Price to FCF topped out at 4.64 in Q2 2022 and bottomed at 12019.87 in Q3 2025.
- Historically, Price to FCF has averaged 649.59 across 5 years, with a median of 16.98 in 2024.
- The widest YoY moves for Price to FCF: up 88.85% in 2025, down 70673.21% in 2025.
- Over 5 years, Price to FCF stood at 24.11 in 2021, then surged by 33.85% to 15.95 in 2022, then plunged by 31.16% to 20.92 in 2023, then soared by 46.41% to 11.21 in 2024, then sank by 107140.51% to 12019.87 in 2025.
- According to Business Quant data, Price to FCF over the past three periods registered 12019.87, 9.54, and 5.18 for Q3 2025, Q2 2025, and Q1 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn |
| 10 | Larimar Therapeutics | 397.87 Mn | 241.60 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | -12,019.87 |
| Jun 30, 2025 | -9.54 |
| Mar 31, 2025 | -5.18 |
| Dec 31, 2024 | -11.21 |
| Sep 30, 2024 | -16.98 |
| Jun 30, 2024 | -32.48 |
| Mar 31, 2024 | -46.43 |
| Dec 31, 2023 | -20.92 |
| Sep 30, 2023 | -18.87 |
| Jun 30, 2023 | -18.36 |
| Mar 31, 2023 | -25.98 |
| Dec 31, 2022 | -15.95 |
| Sep 30, 2022 | -12.10 |
| Jun 30, 2022 | -4.64 |
| Mar 31, 2022 | -9.40 |
| Dec 31, 2021 | -24.11 |
| Sep 30, 2021 | -16.70 |
| Jun 30, 2021 | -14.04 |
| Mar 31, 2021 | -19.46 |
| Dec 31, 2020 | -24.81 |